C4 Therapeutics Presents Positive Biomarker Data for Cemsidomide in Multiple Myeloma Trials
C4 Therapeutics presented new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone and preliminary biomarker data from its Phase 1b trial of cemsidomide in combination with elranatamab. The data demonstrate cemsidomide's immunomodulatory activity, showing robust T-cell activation and expansion, and prevention of T-cell exhaustion. The 75 µg dose level in the Phase 1b trial was declared safe, and the trial is advancing to dose escalation and expansion cohorts. Data from all cohorts are expected in mid-2027.
Key Highlights
- Cemsidomide demonstrated robust T-cell activation in Phase 1 trial with dexamethasone in RRMM patients.
- Biomarker data from Phase 1b trial showed cemsidomide drives T-cell expansion and activation with elranatamab.
- The 75 µg cemsidomide dose level in Phase 1b trial with elranatamab was declared safe by the Safety Data Review Committee.
- Phase 1b trial advancing to dose escalation at 100 µg and expansion at 75 µg cemsidomide dose levels.
- Data from all cohorts in the Phase 1b trial are expected in mid-2027.
Price Impact
More from CCCC
C4 Therapeutics Secures Roche DAC Partnership with $20M Upfront, $1B+ Milestones
C4 Therapeutics Q2 Net Loss $23.6M, EPS $0.18; Cemsidomide Trials On Track
C4 Therapeutics Stockholders Elect Directors, Approve Plan Amendment